91 filings
Page 4 of 5
8-K
xo3wm
3 Nov 15
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
pddbfq1gy3cw
7 Aug 15
Departure of Directors or Certain Officers
12:00am
8-K
f93q2nxp9vd1
27 Apr 15
Departure of Directors or Certain Officers
12:00am
8-K
9kam 1gsnlcq
31 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
j0s 8jbr077h
29 Dec 14
Departure of Directors or Certain Officers
12:00am
8-K
nawiglgc3k q3
24 Oct 14
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
12:00am
8-K
oudbs1yycb 4v
24 Sep 14
Cellceutix Provides Update to Shareholders
12:00am
8-K
tcq62y6v r5s7270kf
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
q2mgal 5i3
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
ch7 zszohdh
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am
8-K
evlcxs8i2rb2xsl1im
5 Jun 13
Changes in Registrant's Certifying Accountant
12:00am
8-K
vl9g 5s0ml7rb18tjt
8 Mar 13
Unregistered Sales of Equity Securities
12:00am
8-K
mbe0ayswc3 okinylv75
4 Mar 13
Cellceutix Signs with Leading Cancer Center For Licensing New Drug
12:00am
8-K
985 t1gl2l0zl8
8 Jan 13
Termination of a Material Definitive Agreement
12:00am
8-K
j6lp wltgoh7p
27 Dec 12
Regulation FD Disclosure
12:00am
8-K
17i6a
26 Dec 12
Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
12:00am
8-K
xes7it2zx
10 Dec 12
Entry into a Material Definitive Agreement
12:00am
8-K
zr6qjfc
29 Jun 12
Unregistered Sales of Equity Securities
12:00am
8-K
1s8ojxcc
22 Jun 12
Cellceutix Approved By FDA to Proceed with Clinical Trials on Novel Cancer Drug
12:00am
8-K
g3c03yi0m8prl1lo
10 May 12
Unregistered Sales of Equity Securities
12:00am